Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLOROQUINE PHOSPHATE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive strains,Treatment of extraintestinal amebiasis (as an adjunct),Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label),Treatment of porphyria cutanea tarda (off-label)
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Hepatic metabolism via CYP2C8 and CYP3A4 to major metabolite desethylchloroquine; other minor metabolites. Renal excretion of parent drug and metabolites.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
50-60% bound to plasma proteins, primarily albumin.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Vd: 100-150 L/kg (range 50-200 L/kg); extremely large indicating extensive tissue penetration and accumulation.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral: 80-90% (rapidly absorbed from GI tract); bioavailability is nearly complete with food enhancing absorption.
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
For Cr Cl <10 m L/min: use 50% of normal dose. For Cr Cl 10-50 m L/min: no adjustment required. For intermittent hemodialysis: no supplemental dose needed.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Severe impairment (Child-Pugh C): maximum 300 mg base (500 mg phosphate) every 12 hours; monitor for toxicity. Mild to moderate impairment: no adjustment needed.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
For malaria: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2 days, then 5 mg base/kg (8.3 mg phosphate/kg) orally once daily for 3 days. Maximum single dose: 600 mg base (1 g phosphate). For extraintestinal amebiasis: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2-3 weeks (max 300 mg base/day).
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
No specific dose adjustment; use with caution due to increased risk of QT prolongation and accumulation with renal impairment. Consider lower initial dose and monitor renal function.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
None explicitly required in current FDA labeling for chloroquine; however, serious adverse effects such as irreversible retinal damage, cardiac toxicity, and hypoglycemia are well-documented. Not receiving a black box warning in standard product labeling.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Retinopathy: irreversible retinal damage with prolonged use; baseline and periodic ophthalmologic exams recommended for chronic therapy.,Cardiac toxicity: QTc prolongation, ventricular arrhythmias, cardiomyopathy; avoid in patients with pre-existing cardiac conditions or concurrent QTc-prolonging drugs.,Hypoglycemia: can cause severe hypoglycemia, especially in diabetics.,Neuropsychiatric effects: seizures, psychosis, suicidal ideation.,Hematologic toxicity: agranulocytosis, aplastic anemia (rare).,Hepatotoxicity: elevated liver enzymes, hepatic failure.,Ototoxicity: irreversible hearing loss.,G6PD deficiency: hemolytic anemia risk with acute hemolysis.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or visual field changes,Pregnancy (especially first trimester) due to potential fetal harm; use for malaria only if benefit outweighs risk,Lactation: caution, excreted in breast milk,G6PD deficiency (relative contraindication; may cause hemolysis)
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
No specific food restrictions. Absorption enhanced by food; take with meals to reduce GI upset. Avoid grapefruit juice if QT prolongation concern.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trimesters: no specific fetal risks documented at standard doses; however, high doses (e.g., for malaria treatment) may cause retinal toxicity or ototoxicity. Overall, considered low teratogenic risk, but benefit-risk assessment required.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Chloroquine is excreted into breast milk in small amounts (M/P ratio approximately 0.3-0.5). Infant dose is estimated <5% of maternal weight-adjusted dose. No adverse effects in breastfed infants reported. Considered compatible with breastfeeding.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No dose adjustment required for prophylaxis or treatment of malaria in pregnancy (standard adult dosing). For autoimmune indications (e.g., lupus, rheumatoid arthritis), maintain lowest effective dose (e.g., 250 mg daily of chloroquine base equivalent). Increased clearance in pregnancy may necessitate therapeutic drug monitoring in rare cases, but standard dosing is typically sufficient.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Chloroquine has a narrow therapeutic index; toxicity can cause retinopathy, especially with cumulative doses >460g base. Baseline and annual eye exams are mandatory. For acute malaria, may need loading dose. Contraindicated in G6PD deficiency due to hemolysis risk. QT prolongation possible; avoid with other QT-prolonging drugs.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take exactly as prescribed; do not miss doses or double up.,Can cause blurred vision; avoid driving until vision clears.,Report vision changes, hearing loss, or unusual bleeding immediately.,May cause GI upset; take with food or milk.,Finishing full course is critical even if symptoms improve.,Use sunscreen; may increase sensitivity to sunlight.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Chloroquine inhibits CYP2C8, CYP2D6, and CYP3A4, key enzymes responsible for the metabolism of nilotinib. This inhibition can significantly increase nilotinib plasma concentrations, elevating the risk of severe adverse effects such as QTc prolongation, hepatotoxicity, and myelosuppression. Concurrent use may also exacerbate the risk of cardiotoxicity, including arrhythmias and sudden cardiac death, due to additive effects on cardiac repolarization."
"Amiloride, a potassium-sparing diuretic, may reduce the antihypertensive efficacy of chloroquine, an antimalarial agent. This interaction arises from amiloride's inhibition of renal tubular sodium reabsorption, which can alter electrolyte balance and potentially blunt the hypotensive effects of chloroquine, leading to suboptimal blood pressure control. In clinical practice, this may result in diminished antihypertensive response, requiring dose adjustments or alternative therapies."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLOROQUINE PHOSPHATE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
CHLOROQUINE PHOSPHATE is a Antimalarial that works by Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLOROQUINE PHOSPHATE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLOROQUINE PHOSPHATE is: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CHLOROQUINE PHOSPHATE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE. Primaquine may increase the QTc-prolonging activities of Chloroquine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CHLOROQUINE PHOSPHATE is classified as Category C. Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trime. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.